423 A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer

423 A phase 2 study of ibrutinib as neoadjuvant therapy in patients with localized prostate cancer

Bibliographic Details
Main Authors:	Lawrence Fong, Russell Pachynski, Peter Oppelt, Melissa Reimers, Cody Weimholt, Katie Slane, Jason Frankel, Robert Figenshau, Eric Kim, Gerald Andriole
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
by: Dhruv Bansal, et al.
Published: (2021-01-01)

Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance
by: Dhivya Sridaran, et al.
Published: (2022-11-01)

How to use ibrutinib
by: Е. А. Nikitin, et al.
Published: (2017-04-01)

Ibrutinib-induced cardiomyopathy
by: Htay Htay Kyi, et al.
Published: (2019-01-01)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
by: Eric H. Kim, et al.
Published: (2018-01-01)

Whole slide image with image analysis of atypical bile duct brushing: Quantitative features predictive of malignancy
by: Brian T Collins, et al.
Published: (2015-01-01)

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
by: Gellért Balázs Karvaly, et al.
Published: (2022-07-01)

Ibrutinib-Induced Skin Rash
by: Sudhir Kirar, et al.
Published: (2021-02-01)

Arrhythmia Patterns in Patients on Ibrutinib
by: Muhammad Fazal, et al.
Published: (2022-01-01)

PGT 423 - Teorl-Teori Personaliti
by: PPIP, Pusat Pengajian Ilmu Pendidikan
Published: (1997)

PGT 423 Teori-Teori Personaliti
by: PPIP, Pusat Pengajian Ilmu Pendidikan
Published: (1997)

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax
by: Rocio Figueroa, et al.
Published: (2020-11-01)

MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer
by: Carmela Ferri, et al.
Published: (2022-01-01)

Invasive Aspergillosis in Patients Treated With Ibrutinib
by: Moritz Fürstenau, et al.
Published: (2020-04-01)

Electrocardiographic Changes Associated With Ibrutinib Exposure
by: Michael G. Fradley MD, et al.
Published: (2020-06-01)

Cystoid macular edema secondary to ibrutinib
by: Ravid Ben-Avi, et al.
Published: (2022-06-01)

Ibrutinib dose modifications in the management of CLL
by: Camille Hardy-Abeloos, et al.
Published: (2020-06-01)

Ibrutinib: A narrative drug review
by: Pritesh Naresh Munot, et al.
Published: (2020-01-01)

EEM 423 – KEJURUTERAAN KEBOLEHPERCAYAAN JAN. 2012
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2012)

EEM 423 – KEJURUTERAAN KEBOLEHPERCAYAAN November 2008
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2008)

EEM423 – RELIABILITY ENGINEERING JANUARY 2013
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2013)

EEM423 – RELIABILITY ENGINEERING JANUARY 2014
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2014)

EEM423 - KEJURUTERAAN KEBOLEHPERCAYAAN - NOVEMBER 2008.
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2008)

EEM423 - KEJURUTERAAN KEBOLEHPERCAYAAN - NOVEMBER 2008.
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2008)

ZSE 423/4 - SPEKTROSKOPI APRIL 1997.
by: PPSF, Pusat Pengajian Sains Fizik
Published: (1997)

ZSE 423 - SPEKTROSKOPI OKT-NOV 1995.
by: PPSF, Pusat Pengajian Sains Fizik
Published: (1995)

EEM 423 - KEJURUTERAAN KEBOLEHPERCAYAAN NOVEMBER 2010
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2010)

ZSE 423 - Spektroskopi Oktober/November 1995
by: PPSF, Pusat Pengajian Sains Fizik
Published: (1995)

EEM 423 - KEJURUTERAAN KEBOLEHPERCAYAAN NOV 05.
by: PPKEE, Pusat Pengajian Kejuruteraan Elektrik & Elektronik
Published: (2005)

1109 Chemerin suppresses prostate tumor growth by modulating the recruitment of effector NK and CD8+ T-cells into the tumor microenvironment
by: Bo Peng, et al.
Published: (2023-11-01)

Rare but Serious: Ibrutinib Induced Liver Failure
by: Fleur S. Kleijwegt, et al.
Published: (2019-12-01)

From antibiotics to ibrutinib: An array of treatment modalities
by: Catherine Thieblemont
Published: (2018-06-01)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
by: Fangmin Huang, et al.
Published: (2023-09-01)

IBRUTINIB RELATED NEUROPATHY: A CASE REPORT
by: Zeynep Tuğba Güven, et al.
Published: (2023-10-01)

Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
by: Kaleigh E. Lindholm, et al.
Published: (2021-08-01)

Ibrutinib-Induced Pancreatitis in Patients with Waldenstrom Macroglobulinemia
by: Nurhilal Büyükkurt, et al.
Published: (2023-06-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical
by: Dong R, et al.
Published: (2022-09-01)

Complex dispersions of poloxamers and mesoporous carriers with ibrutinib
by: Igor A. Dain, et al.
Published: (2022-11-01)

Ibrutinib-associated alveolar hemorrhage and spontaneous hemothorax
by: Ismail Tombul, et al.
Published: (2022-03-01)